Who are Leuprolide Acetate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Yselty, Orgovyx, Orilissa, Firmagon, Plenaxis, Trelstar.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/leuprolide-acetate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Leuprolide Acetate — Competitive Intelligence Brief

Leuprolide Acetate (leuprolide-acetate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: leuprorelin. Area: Oncology.

marketed leuprorelin Gonadotropin-releasing hormone receptor Oncology Live · refreshed every 30 min

Target snapshot

Leuprolide Acetate (leuprolide-acetate) — Pfizer. Leuprolide acetate is a manufactured version of a hormone that regulates growth and development, used to treat hormone-related conditions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Leuprolide Acetate TARGET	leuprolide-acetate	Pfizer	marketed	leuprorelin	Gonadotropin-releasing hormone receptor	1985-01-01
Yselty	LINZAGOLIX	Obseva Ireland Ltd	marketed		Gonadotropin-releasing hormone receptor	2022-01-01
Orgovyx	relugolix	MYOVANT SCIENCES	marketed	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	Gonadotropin-releasing hormone receptor	2020-01-01
Orilissa	ELAGOLIX	AbbVie	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2018-01-01
Firmagon	degarelix	Ferring	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2008-01-01
Plenaxis	ABARELIX	Speciality European	marketed	abarelix	Gonadotropin-releasing hormone receptor	2003-01-01
Trelstar	triptorelin	Verity	marketed	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Leuprolide Acetate · 9617303 · US
2031-02-05 — Leuprolide Acetate · 8921326 · US
2036-02-25 — Orgovyx · 10350170 · US
2037-09-29 — Orgovyx · 10449191 · US
2037-09-29 — Orgovyx · 11583526 · US
2037-09-29 — Orgovyx · 11033551 · US
2037-09-29 — Orgovyx · 10786501 · US

Sponsor landscape (leuprorelin class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Leuprolide Acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/leuprolide-acetate. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab